Oklo chosen by DOE to advance Groves 2 Forge isotope production facility
Oklo Inc. was selected by the U.S. Department of Energy’s Nuclear Energy Launch Pad initiative to move forward with its Groves 2 Forge facility. The project will expand the Groves Isotope Test Reactor’s capabilities to produce, process and purify critical isotopes, initially focusing on lutetium‑177 for cancer treatments. DOE’s program includes 12 developers across 13 projects and provides a pathway for domestic reactor and isotope‑fuel cycle development. Oklo’s co‑founder and CEO Jacob DeWitte and DOE Acting Deputy Assistant Secretary Chimi Zacot highlighted the rapid criticality achievement and the private‑public collaboration that enables the next phase.
Why it matters
Oklo says the selection will allow it to transition Groves 2 Forge from pilot operations to commercial‑scale isotope production under U.S. Nuclear Regulatory Commission licenses, creating a new revenue stream from domestic isotope supply.
Key facts
- 1Oklo was selected to advance its Groves 2 Forge facility as part of the DOE Nuclear Energy Launch Pad initiative. newspressnow.com
- 2The initiative includes 12 developers across 13 projects. investing.com
- 3Groves 2 Forge will focus on producing lutetium‑177, an isotope used in targeted cancer treatments. investing.com
- 4Oklo’s Groves Isotope Test Reactor reached criticality in less than a year under the DOE Reactor Pilot Program. gurufocus.com
- 5Jacob DeWitte, Oklo co‑founder and CEO, said Groves 2 Forge will add capabilities needed to irradiate target materials and process valuable isotopes. investing.com
- 6Chimi Zacot, Acting Deputy Assistant Secretary for Nuclear Reactors, praised Oklo’s private‑sector collaboration with DOE. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.